rs34380494

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2

The NM_004268.5(MED17):​c.1482A>G​(p.Gln494Gln) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00211 in 1,601,822 control chromosomes in the GnomAD database, including 65 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.011 ( 33 hom., cov: 32)
Exomes 𝑓: 0.0012 ( 32 hom. )

Consequence

MED17
NM_004268.5 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: 1.85

Publications

2 publications found
Variant links:
Genes affected
MED17 (HGNC:2375): (mediator complex subunit 17) The activation of gene transcription is a multistep process that is triggered by factors that recognize transcriptional enhancer sites in DNA. These factors work with co-activators to direct transcriptional initiation by the RNA polymerase II apparatus. The protein encoded by this gene is a subunit of the CRSP (cofactor required for SP1 activation) complex, which, along with TFIID, is required for efficient activation by SP1. This protein is also a component of other multisubunit complexes e.g. thyroid hormone receptor-(TR-) associated proteins which interact with TR and facilitate TR function on DNA templates in conjunction with initiation factors and cofactors. [provided by RefSeq, Jul 2008]
MED17 Gene-Disease associations (from GenCC):
  • infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: G2P, Labcorp Genetics (formerly Invitae), Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.51).
BP6
Variant 11-93807533-A-G is Benign according to our data. Variant chr11-93807533-A-G is described in ClinVar as [Likely_benign]. Clinvar id is 129595.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=1.85 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.0111 (1695/152316) while in subpopulation AFR AF = 0.0378 (1570/41564). AF 95% confidence interval is 0.0362. There are 33 homozygotes in GnomAd4. There are 811 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 33 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MED17NM_004268.5 linkc.1482A>G p.Gln494Gln synonymous_variant Exon 10 of 12 ENST00000251871.9 NP_004259.3 Q9NVC6-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MED17ENST00000251871.9 linkc.1482A>G p.Gln494Gln synonymous_variant Exon 10 of 12 1 NM_004268.5 ENSP00000251871.3 Q9NVC6-1
ENSG00000284057ENST00000638767.1 linkc.2043A>G p.Gln681Gln synonymous_variant Exon 17 of 19 5 ENSP00000492220.1 A0A1W2PRB8

Frequencies

GnomAD3 genomes
AF:
0.0111
AC:
1687
AN:
152200
Hom.:
33
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0377
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00536
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000192
Gnomad SAS
AF:
0.00228
Gnomad FIN
AF:
0.0000942
Gnomad MID
AF:
0.00316
Gnomad NFE
AF:
0.0000441
Gnomad OTH
AF:
0.0124
GnomAD2 exomes
AF:
0.00305
AC:
767
AN:
251370
AF XY:
0.00248
show subpopulations
Gnomad AFR exome
AF:
0.0385
Gnomad AMR exome
AF:
0.00139
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.000163
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000880
Gnomad OTH exome
AF:
0.000979
GnomAD4 exome
AF:
0.00117
AC:
1689
AN:
1449506
Hom.:
32
Cov.:
28
AF XY:
0.00115
AC XY:
828
AN XY:
722030
show subpopulations
African (AFR)
AF:
0.0358
AC:
1185
AN:
33144
American (AMR)
AF:
0.00201
AC:
90
AN:
44704
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26042
East Asian (EAS)
AF:
0.0000758
AC:
3
AN:
39586
South Asian (SAS)
AF:
0.00238
AC:
205
AN:
86006
European-Finnish (FIN)
AF:
0.0000375
AC:
2
AN:
53404
Middle Eastern (MID)
AF:
0.00226
AC:
13
AN:
5750
European-Non Finnish (NFE)
AF:
0.0000554
AC:
61
AN:
1100886
Other (OTH)
AF:
0.00217
AC:
130
AN:
59984
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.459
Heterozygous variant carriers
0
76
152
229
305
381
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
42
84
126
168
210
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0111
AC:
1695
AN:
152316
Hom.:
33
Cov.:
32
AF XY:
0.0109
AC XY:
811
AN XY:
74476
show subpopulations
African (AFR)
AF:
0.0378
AC:
1570
AN:
41564
American (AMR)
AF:
0.00536
AC:
82
AN:
15304
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.000193
AC:
1
AN:
5184
South Asian (SAS)
AF:
0.00228
AC:
11
AN:
4824
European-Finnish (FIN)
AF:
0.0000942
AC:
1
AN:
10616
Middle Eastern (MID)
AF:
0.00340
AC:
1
AN:
294
European-Non Finnish (NFE)
AF:
0.0000441
AC:
3
AN:
68034
Other (OTH)
AF:
0.0123
AC:
26
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
84
168
253
337
421
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00378
Hom.:
6
Bravo
AF:
0.0123
Asia WGS
AF:
0.00462
AC:
16
AN:
3478
EpiCase
AF:
0.000164
EpiControl
AF:
0.000237

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Jan 27, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Apr 03, 2021
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly Benign:2
Sep 16, 2020
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Aug 17, 2021
Fulgent Genetics, Fulgent Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1
Jun 26, 2013
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.51
CADD
Benign
5.9
DANN
Benign
0.59
PhyloP100
1.9
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs34380494; hg19: chr11-93540699; API